Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Application form for Ad26 clinical vectors and MVA-BN clinical vectors contained in investigational products for human use

Proposed period of release:
01/04/2021 to 01/04/2031

Name of the Institute(s) or Company(ies)
Centre for human drug research, The Netherlands;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Ad26 clinical vector is derived from the human Adenovirus group D type 26 (genus Mastadenoviridae)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Human adenovirus type 26MastadenovirusHuman adenovirus group D-Type 26-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known